Adocia SA · EURONEXT:ADOC
Adocia SA — Investor Presentation (January 2018)
40 slides from Adocia SA's investor presentation, January 2018
Slide 1: Corporate Presentation January 2018
CORPORATE PRESENTATION JANUARY 2018
Slide 2: Disclaimer
INTRO Disclaimer This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying t
Slide 3: ADOCIA in summary
ADOCIA ADOCIA in summary Business model delivering cost-effective innovation based on already-approved 1 proteins, enhanced with BioChaperone® Key clinical assets including ultra-rapid insulin BC Lispro, glargine-based modern 2 premix BC Combo and ready-to-use BC Glucagon 3 First-in-class combinatio
Slide 4: Management Team
ADOCIA Management Team Gérard Soula Olivier Soula Valérie Rémi Soula Steve Daly Stan Glezer PhD, MBA PhD, MBA Danaguezian PhD, MBA MD, MBA President & CEO Deputy General Manager, Chief Financial Officer Director of BD & IP US General Manager Chief Medical Officer Co-founder R&D Director Co-founder C
Slide 5: Our mission is dedicated to improving lives
ADOCIA Our mission is dedicated to improving lives Develop treatments for diabetes and other metabolic conditions in a more physiologic and affordable way 5 January 2018
Slide 6: BioChaperone Technology
BIOCHAPERONE TECHNOLOGY 6 January 2018
Slide 7: BioChaperone unlocks the potential of proteins and peptides
ADOCIA BioChaperone® unlocks the potential of proteins and peptides and their combinations in a cost-effective way BioChaperone® Proteins and peptides (insulin, GLP-1 RA, pramlintide, (library of molecules) glucagon; teduglutide…) [BioChaperone® Protein] Complex ✓ Improved solubility ✓Improved stabi
Slide 8: Adocia is diversifying its portfolio beyond diabetes
ADOCIA Adocia is diversifying its portfolio beyond diabetes Diabetes clinical pipeline Diabetes preclinical pipeline In vitro PC Phase I/II Phase III In vitro PC Phase I/II BC Lispro U100 BC Glucagon BC Lispro U200 BC Pram rHI BC Combo (BC Gla Lis) BC Gla GLP-1 Other indications - Development HinsBe
Slide 9: Adocia Diabetes Portfolio
ADOCIA DIABETES PORTFOLIO NEXT GENERATION TREATMENTS FOR BETTER OUTCOMES 9 January 2018
Slide 10: There remains a real medical need in diabetes
DIABETES There remains a real medical need in diabetes 26M2 ▪ Despite 100 years of medical treatment, long-term consequences of diabetes remain a major issue 415M1 on insulin people with diabetes in 2015 ▪ There is a need to address the underlying complexity of diabetes ▪ With more granularity ▪ In
Slide 11: BioChaperone Lead Insulin Clinical Programs
BIOCHAPERONE LEAD INSULIN CLINICAL PROGRAMS BIOCHAPERONE LISPRO & BIOCHAPERONE COMBO 11 January 2018
Slide 12: BioChaperone Lispro: ultra-rapid insulin in pens and pumps
BC LISPRO BioChaperone Lispro: an ultra-rapid insulin showing potential best-in-class performance in pens and pumps ▪ “Ultra-rapid” insulin is a new class of prandial insulin $7B ▪ Novo Nordisk Fiasp® (faster-acting insulin aspart) is the first approved product Prandial ▪ Introduced at price parity
Slide 13: Partnering BioChaperone Lispro is Adocia's priority
BC LISPRO Partnering BioChaperone Lispro is Adocia’s priority Post-meal glycaemia in T1D ▪ Accelerated absorption and better post-prandial control for BC Lispro U100 vs. Humalog® AUC0-2h: ▪ Consistent results obtained in 252 people with T1D & T2D -61%* vs. Humalog® & Novolog® ▪ BC Lispro has shown s
Slide 14: BC Combo: alternative to premix insulin for type 2 diabetes
BC COMBO A safer and more efficient alternative to premix insulin for the treatment of type 2 diabetes ▪ Premix insulin provides basal and prandial coverage with 2 injections/day $5B (vs. up to 4 for basal + prandial insulin) 65%1 Premix insulin ▪ In China, premix is the main insulin product in volu
Slide 15: BC Combo superior prandial and basal control vs premix
BC COMBO BC Combo has shown superior prandial and basal control compared to premix insulin Post-meal glycemia in T1D ▪ 4 successful Phase 1/2 clinical studies (2 in T1D & 2 in T2D)(1,2) Individualized doses ▪ In T1D & T2D BC Combo showed superiority vs. Humalog Mix25 (1,2): ∆AUC0-2h ✓ Less hyperglyc
Slide 16: Multihormonal Treatments for Diabetes
MULTIHORMONAL TREATMENTS FOR DIABETES 16 January 2018
Slide 17: Multi-hormonal physiologic treatments in a cost-effective way
STRATEGY Adocia aims to provide multi-hormonal physiologic treatments in a cost-effective way ▪ Multiple complementary hormones are required to more closely mimic normal physiology for: ▪ Tighter glucose control and reduced risk of hypoglycemia ▪ Weight loss ▪ Additional long term medical benefits (
Slide 18: Innovative multi-hormonal approaches for diabetes and obesity
RATIONALE Innovative multi-hormonal approaches aim to improve diabetes and obesity management Insulin In combination BC Glargine GLP-1 (T2D) BC Pramlintide rhIns (T1D & T2D) GLP-1 Amylin In combination In a dual-chamber pump BC Glucagon GLP-1 BC Glucagon with Insulin (T1D) (Obesity) Glucagon As a se
Slide 19: Time-sensitive hormonal pattern maintains normo-glycemia
DIABETES In non-diabetic people, a time-sensitive hormonal pattern maintains normo-glycemia Schematic representation of hormonal pattern1 Insulin Without diabetes With Type 1 diabetes (T1D) Level of secretion Amylin (relative scale) Glucagon GLP-1 GLP-1 Glucagon Insulin Amylin 0 1 2 3 4 5 6 0 1 2 3
Slide 20: Amylin, the Other Missing Hormone in Type 1 Diabetes
BC PRAM INS Amylin, the Other Missing Hormone in Type 1 Diabetes h u m a n in s u lin ▪ Amylin is co-secreted with insulin by pancreatic beta cells. Postprandial blood h u m a n in s u lin + a m yglucose lin a n a lo g 6 ▪ Secretion of Amylin is deficient in T1D and altered in T2D h u m a n in s u l
Slide 21: Clinically proven benefits of co-administering insulin with pramlintide
BC PRAM INS Leveraging the clinically proven benefits of co-administering prandial insulin with pramlintide Change in prandial Change in weight insulin dose after 6 after 6 months (kg) months (%) 0 ▪ Pramlintide (amylin analog) three times a day has 0 demonstrated synergistic benefits when administe
Slide 22: Prandial insulin-based multi-hormonal treatment for T1D
BC PRAM INS Enabling prandial insulin-based multi-hormonal treatment to improve long-term outcomes in T1D ▪ Tighter glycemic control lowers the risk of severe complications1, and insulin alone, while life-saving, is insufficient to optimize control ▪ Multiple hormonal combinations could be the next
Slide 23: Ready-to-use aqueous formulation of human glucagon
BC A ready-to-use aqueous formulation of human glucagon GLUCAGON for acute and chronic use ▪ BioChaperone Glucagon is an aqueous formulation of human glucagon supporting: ▪ Ready-to-use rescue treatment for severe hypoglycemia ▪ Current market largely underserved due to poor glucagon kits usability1
Slide 24: Positive first-in-man data support further development
BC GLUCAGON Positive first-in-man data support further development ▪ Positive first-in-man results. BioChaperone Glucagon was shown to: Preclinical study in pigs Mean blood glucose ▪ Be safe and well tolerated in people with type 1 diabetes Blood Glucose (mg/dL) ▪ Efficiently rescue 100% participant
Slide 25: Expanding the Portfolio
EXPANDING THE PORTFOLIO LEVERAGING BIOCHAPERONE TRACK-RECORD TO ADDRESS NEW THERAPEUTIC TARGETS 25 January 2018
Slide 26: Leveraging BioChaperone beyond diabetes
PORTFOLIO EXPANSION Adocia is leveraging BioChaperone® to unlock the potential of proteins and peptides beyond diabetes ▪ Adocia intends to expand the use of BioChaperone to bring cost-effective innovation to other therapeutic areas with high unmet needs by leveraging: ▪ Extensive BioChaperone® trac
Slide 27: BioChaperone Glucagon-GLP-1 for nondiabetic obesity
BC GCG GLP-1 BioChaperone Glucagon-GLP-1 for the treatment of nondiabetic obesity ▪ Obesity prevalence has tripled from 1975 to 2016 globally2, triggering the development of 36.5%1 more aggressive treatment regimens: of US adults ▪ GLP-1 RA liraglutide (Saxenda®, Novo Nordisk) is approved for weight
Slide 28: BioChaperone GLP-2 for short-bowel syndrome
BC GLP-2 BioChaperone GLP-2: a ready-to-use solution to improve the life of people with short-bowel syndrome (SBS) ▪ Approx. 20,000 people with SBS require parenteral Gattex® (teduglutide) BioChaperone Teduglutide nutrition in EU & US1 × Lyophilisate ✓ Stable aqueous solution ▪ Prevalence and awaren
Slide 29: Key financial elements
ADOCIA Key financial elements Financial summary Shareholders’ equity (November, 2017) Analysts ▪ Listed on Euronext Paris (ADOC) Free Float Soula Family 22.1 % ▪ Jefferies (Peter Welford) 60.5% ▪ Kepler Market (Arsène Guekam) ▪ 6.9M shares outstanding ▪ Oddo (Sébastien Malafosse – Pierre Corby) ▪ Lo
Slide 30: Key assets status
ADOCIA Key assets status Clinical programs Preclinical programs ▪ BC LISPRO ▪ BC PRAMLINTIDE INSULIN ▪ Phase 3-ready asset, available for global licensing ▪ First-in-man study planned in H1 18 New! ✓ Positive Phase 1b topline results vs. Fiasp® and Novolog® (Q4 17) ▪ BC GLUCAGON GLP-1 ▪ BC COMBO ▪ F
Slide 31: Thank you for your kind interest
THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 31 January 2018
Slide 32: Appendix
APPENDIX 32 January 2018 = ADOCIA i
Slide 33: Top-tier Medical Advisory Board
ADOCIA Adocia is supported by a top-tier Medical Advisory Board ▪ 12 highly renowned international thought-leaders: ▪ Dr. Jay Skyler, MD, Chairman, University of Miami (US) ▪ Dr. Vanita Aroda, MD, MedStar Health Research Institute (US) ▪ Dr. Bruce Bode, MD, Emory University (US) ▪ Dr. John Buse, MD,
Slide 34: Upcoming major diabetes conferences
EVENTS Upcoming major diabetes conferences ▪ Adocia will submit abstracts for publication and intends to attend the following conferences: ▪ 11th International Conference on Advanced Technologies & Treatments for Diabetes, February 14-17, 2018, Vienna, Austria ▪ 78th Scientific Sessions of the Ameri
Slide 35: BC Lispro results vs Humalog U100 in T1DM
BC LISPRO Results summary compared to Humalog U100 in T1DM subjects 294-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Biochaperone Lispro: Shorter TMAX, Higher CMAX ▪ BioChaperone Lispro in comparison with and Similar Exposure Greater Earlier Exposure: Faster In Humalo
Slide 36: BC Combo results vs Lispro Mix 75/25 in T1DM
BC COMBO Results summary compared to Conventional Lispro Mix 75/25 in T1DM subjects 295-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Mean Unadjusted BG Profiles ± SEM Over 6hr After s.c. Cumulative Percentage of Subjects With BG Values < 63 mg/dL ▪ In this solid mixed
Slide 37: BC Combo results vs Humalog 75/25 in T2DM
BC COMBO Results summary compared to Humalog 75/25 in T2DM subjects 942-P in 12-B Clinical Therapeutics/ New Technology-Insulins, June 11, 2016, 76th ADA Scientific Sessions Smoothed GIR Profiles (0-30h) of 0.8 U/kg BioChaperone Combo, 0.8 Smoothed GIR Profiles (0-2h) of 0.8 U/kg BioChaperone ▪ In t
Slide 38: HinsBet: affordable prandial insulin
HINSBET Affordable prandial insulin for price-sensitive populations ▪ HinsBet is a formulation of human insulin designed to act as rapidly as an insulin analog $1B ▪ 77% of people with diabetes live in low- and middle-income countries Human prandial ▪ For economic reasons, human insulin is the most
Slide 39: HinsBet similar early action to fast-acting analog
HINSBET HinsBet displays similar early action to fast-acting insulin analog in T1D patients Early Glucose Infusion Rate (U100)1 ▪ Meal-test study in 36 T1D confirmed PD profile in first hour2 (Oct 2016) ▪ During first hour after the meal, HinsBet: ✓ 70% earlier onset ▪ Significantly reduced glucose
Slide 40: Intensification options over basal insulin for T2D
BC Efficient and affordable intensification options over GLAR GLP-1 basal insulin for T2D $2.2B1 ▪ Combinations of basal insulin and GLP-1 are a new class of treatment for T2D 2023 Forecast ▪ 50% patients are not controlled on basal insulin alone2 Basal-GLP1 ▪ 2 products recently approved in EU & US